Home Page
Since 2018, generous support from Gillette donors has fueled progress in Rett syndrome research, education, outreach, and family support.
IRSF designates Gillette Children’s Rett Syndrome Program a Center of Excellence.
Thanks to philanthropy and the dedication of our exceptional care team, Gillette has emerged as one of the premier destinations for Rett syndrome care. We are proud to be one of just 18 institutions in the US designated as a Center of Excellence by the International Rett Syndrome Foundation (IRSF) The program is led by Arthur Beisang, MD, complex care physician and director of Gillette Children’s Rett Syndrome Center of Excellence.
Learn about Rett Syndrome care at Gillette Children's.
Daybue provides promising gene therapy to treat Rett Syndrome
Two years ago, Gillette began offering Daybue—the first FDA-approved treatment for Rett syndrome—following tireless advocacy and coordination by our providers, research staff, pharmacists, and prior authorization team. Dr. Beisang played a key role as an investigator in the clinical trials that led to the drug’s approval.
“These patients are improving incrementally, and we see improvements in communication skills, breathing, and overall quality of life,” says Dr. Beisang.
Some Gillette Rett syndrome patients recently participated in an exciting and promising pediatric gene therapy clinical trial. The treatment focuses on what matters most to our families—developmental milestones gained or regained, while maintaining a strong emphasis on safety.>
Rett Syndrome Research fueled by partnerships and supporters
Our physicians and researchers are encouraged by the continued progress and potential advancements in treatment options for individuals with Rett syndrome. These opportunities are a true reflection of how one investment can lead to another, and how vital partnerships are to advance care. Together with patients, families, philanthropic supporters, researchers, clinicians, and healthcare partners, meaningful change is possible.
Gillette is grateful for the continued support of donors who accelerate breakthroughs that improve the lives of our patients.
